

The Velvet Rope Of Weight Loss Drugs

Written by The Life Science Feed Editorial Team · Published 28 May 2026 · Edited by Sarah Mitchell

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes (STEP 8). **JAMA**. 2022;327(2):138–150. <https://doi.org/10.1001/jama.2021.23619>
2. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 4). **Diabetes Obes Metab**. 2022;24(8):1553–1564. <https://doi.org/10.1111/dom.14725>
3. Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. **Postgrad Med J**. 2020;96(1133):156–161. <https://doi.org/10.1136/postgradmedj-2019-137186>
4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases. **Eur Heart J**. 2020;41(2):255–323. <https://doi.org/10.1093/eurheartj/ehz486>
5. Seibert SM, Wood S, Baum SJ, et al. Misperceptions of obesity: people with obesity have excess adiposity — not merely high body weight. **JAMA**. 2021;326(18):1843–1844. <https://doi.org/10.1001/jama.2021.17486>
6. Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. **N Engl J Med**. 2019;381(25):2440–2450. <https://doi.org/10.1056/NEJMsa1909301>
7. Dieleman JL, Squires E, Bui AL, et al. Factors associated with increases in US health care spending, 1996–2013. **JAMA**. 2017;318(17):1668–1678. <https://doi.org/10.1001/jama.2017.15927>
8. Cani PD, Knauf C. How gut microbes talk to organs: the role of endocrine and nervous routes. **Mol Metab**. 2016;5(9):743–752. <https://doi.org/10.1016/j.molmet.2016.05.011>
9. Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis (MAESTRO-NASH). **N Engl J Med**. 2024;390(6):497–509. <https://doi.org/10.1056/NEJMoa2309000>

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com